Rituximab in systemic sclerosis: a protocol for systematic review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRN |
Texto Completo: | https://repositorio.ufrn.br/handle/123456789/55362 |
Resumo: | Background: Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option. The objective is to describe a protocol of a systematic review (SR) that analyzes the scientific evidence on the effects of RTX on SSc. Methods: This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. The databases to be searched are PubMed, Scopus, SciELO, LILACS, ScienceDirect, Web of Science, COCHRANE, WHOLIS, PAHO, and EMBASE. The studies that would be included in SR are clinical trials that evaluate the use of RTX in patients with SSc who meet the classification criteria for the disease according to American College of Rheumatology and European League Against Rheumatism (2013) and/or LeRoy criteria will be included in the SR. The data to be extracted are related to the characteristics of the studies: authors, year of publication, study location, type of study, sample size and age, patient characteristics, duration of intervention, therapeutic scheme, follow-up time, main variables, and main results. Results: In our study, we hope to find articles presenting new evidence supporting treatment of SSc with RTX. Conclusions: The SR will present results of scientific evidence for the effects of RTX in SSc. We hope that the results could strengthen clinical decisions for the best treatment of SSc and guide future researches |
id |
UFRN_02d6f8604a94340f173c864c50b3f0dd |
---|---|
oai_identifier_str |
oai:https://repositorio.ufrn.br:123456789/55362 |
network_acronym_str |
UFRN |
network_name_str |
Repositório Institucional da UFRN |
repository_id_str |
|
spelling |
Piuvezam, GrasielaCaldas, Marina Maria Vieira de FigueiredoBezerra Neto, Francisco AlvesAzevedo, Kesley Pablo Morais dePimenta, Isac Davidson Santiago FernandesOliveira, Ana Katherine da Silveira Gonçalves dehttps://orcid.org/0000-0002-2343-72512023-11-16T19:59:52Z2023-11-16T19:59:52Z2019PIUVEZAM, Grasiela; AZEVEDO, K. P. M. ; CALDAS, M. M. V. F. ; BEZERRA NETO, F. A. ; PIMENTA, I. D. S. F. ; OLIVEIRA, A. K. S. G. Rituximab in systemic sclerosis: a protocol for systematic review. Medicine, v. 98, p. e17110, 2019. DOI: 10.1097/MD.0000000000017110. Disponível em: https://journals.lww.com/md-journal/fulltext/2019/09200/rituximab_in_systemic_sclerosis__a_protocol_for.18.aspx. Aceso em: 13 nov. 2023.https://repositorio.ufrn.br/handle/123456789/5536210.1097/MD.0000000000017110MedicineAttribution 3.0 Brazilhttp://creativecommons.org/licenses/by/3.0/br/info:eu-repo/semantics/openAccesscutaneous fibrosisinterstitial lung diseaserituximabsystematic reviewsystemic sclerosisRituximab in systemic sclerosis: a protocol for systematic reviewinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleBackground: Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option. The objective is to describe a protocol of a systematic review (SR) that analyzes the scientific evidence on the effects of RTX on SSc. Methods: This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. The databases to be searched are PubMed, Scopus, SciELO, LILACS, ScienceDirect, Web of Science, COCHRANE, WHOLIS, PAHO, and EMBASE. The studies that would be included in SR are clinical trials that evaluate the use of RTX in patients with SSc who meet the classification criteria for the disease according to American College of Rheumatology and European League Against Rheumatism (2013) and/or LeRoy criteria will be included in the SR. The data to be extracted are related to the characteristics of the studies: authors, year of publication, study location, type of study, sample size and age, patient characteristics, duration of intervention, therapeutic scheme, follow-up time, main variables, and main results. Results: In our study, we hope to find articles presenting new evidence supporting treatment of SSc with RTX. Conclusions: The SR will present results of scientific evidence for the effects of RTX in SSc. We hope that the results could strengthen clinical decisions for the best treatment of SSc and guide future researchesengreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNORIGINALRituximabSystemicSclerosis_Piuvezam_2019.pdfRituximabSystemicSclerosis_Piuvezam_2019.pdfapplication/pdf205526https://repositorio.ufrn.br/bitstream/123456789/55362/1/RituximabSystemicSclerosis_Piuvezam_2019.pdf4d56cd6ea0810fb390744fb07b9d5bdeMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8914https://repositorio.ufrn.br/bitstream/123456789/55362/2/license_rdf4d2950bda3d176f570a9f8b328dfbbefMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81484https://repositorio.ufrn.br/bitstream/123456789/55362/3/license.txte9597aa2854d128fd968be5edc8a28d9MD53123456789/553622023-11-16 16:59:53.155oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2023-11-16T19:59:53Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false |
dc.title.pt_BR.fl_str_mv |
Rituximab in systemic sclerosis: a protocol for systematic review |
title |
Rituximab in systemic sclerosis: a protocol for systematic review |
spellingShingle |
Rituximab in systemic sclerosis: a protocol for systematic review Piuvezam, Grasiela cutaneous fibrosis interstitial lung disease rituximab systematic review systemic sclerosis |
title_short |
Rituximab in systemic sclerosis: a protocol for systematic review |
title_full |
Rituximab in systemic sclerosis: a protocol for systematic review |
title_fullStr |
Rituximab in systemic sclerosis: a protocol for systematic review |
title_full_unstemmed |
Rituximab in systemic sclerosis: a protocol for systematic review |
title_sort |
Rituximab in systemic sclerosis: a protocol for systematic review |
author |
Piuvezam, Grasiela |
author_facet |
Piuvezam, Grasiela Caldas, Marina Maria Vieira de Figueiredo Bezerra Neto, Francisco Alves Azevedo, Kesley Pablo Morais de Pimenta, Isac Davidson Santiago Fernandes Oliveira, Ana Katherine da Silveira Gonçalves de |
author_role |
author |
author2 |
Caldas, Marina Maria Vieira de Figueiredo Bezerra Neto, Francisco Alves Azevedo, Kesley Pablo Morais de Pimenta, Isac Davidson Santiago Fernandes Oliveira, Ana Katherine da Silveira Gonçalves de |
author2_role |
author author author author author |
dc.contributor.authorID.pt_BR.fl_str_mv |
https://orcid.org/0000-0002-2343-7251 |
dc.contributor.author.fl_str_mv |
Piuvezam, Grasiela Caldas, Marina Maria Vieira de Figueiredo Bezerra Neto, Francisco Alves Azevedo, Kesley Pablo Morais de Pimenta, Isac Davidson Santiago Fernandes Oliveira, Ana Katherine da Silveira Gonçalves de |
dc.subject.por.fl_str_mv |
cutaneous fibrosis interstitial lung disease rituximab systematic review systemic sclerosis |
topic |
cutaneous fibrosis interstitial lung disease rituximab systematic review systemic sclerosis |
description |
Background: Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option. The objective is to describe a protocol of a systematic review (SR) that analyzes the scientific evidence on the effects of RTX on SSc. Methods: This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. The databases to be searched are PubMed, Scopus, SciELO, LILACS, ScienceDirect, Web of Science, COCHRANE, WHOLIS, PAHO, and EMBASE. The studies that would be included in SR are clinical trials that evaluate the use of RTX in patients with SSc who meet the classification criteria for the disease according to American College of Rheumatology and European League Against Rheumatism (2013) and/or LeRoy criteria will be included in the SR. The data to be extracted are related to the characteristics of the studies: authors, year of publication, study location, type of study, sample size and age, patient characteristics, duration of intervention, therapeutic scheme, follow-up time, main variables, and main results. Results: In our study, we hope to find articles presenting new evidence supporting treatment of SSc with RTX. Conclusions: The SR will present results of scientific evidence for the effects of RTX in SSc. We hope that the results could strengthen clinical decisions for the best treatment of SSc and guide future researches |
publishDate |
2019 |
dc.date.issued.fl_str_mv |
2019 |
dc.date.accessioned.fl_str_mv |
2023-11-16T19:59:52Z |
dc.date.available.fl_str_mv |
2023-11-16T19:59:52Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
PIUVEZAM, Grasiela; AZEVEDO, K. P. M. ; CALDAS, M. M. V. F. ; BEZERRA NETO, F. A. ; PIMENTA, I. D. S. F. ; OLIVEIRA, A. K. S. G. Rituximab in systemic sclerosis: a protocol for systematic review. Medicine, v. 98, p. e17110, 2019. DOI: 10.1097/MD.0000000000017110. Disponível em: https://journals.lww.com/md-journal/fulltext/2019/09200/rituximab_in_systemic_sclerosis__a_protocol_for.18.aspx. Aceso em: 13 nov. 2023. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufrn.br/handle/123456789/55362 |
dc.identifier.doi.none.fl_str_mv |
10.1097/MD.0000000000017110 |
identifier_str_mv |
PIUVEZAM, Grasiela; AZEVEDO, K. P. M. ; CALDAS, M. M. V. F. ; BEZERRA NETO, F. A. ; PIMENTA, I. D. S. F. ; OLIVEIRA, A. K. S. G. Rituximab in systemic sclerosis: a protocol for systematic review. Medicine, v. 98, p. e17110, 2019. DOI: 10.1097/MD.0000000000017110. Disponível em: https://journals.lww.com/md-journal/fulltext/2019/09200/rituximab_in_systemic_sclerosis__a_protocol_for.18.aspx. Aceso em: 13 nov. 2023. 10.1097/MD.0000000000017110 |
url |
https://repositorio.ufrn.br/handle/123456789/55362 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
Attribution 3.0 Brazil http://creativecommons.org/licenses/by/3.0/br/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution 3.0 Brazil http://creativecommons.org/licenses/by/3.0/br/ |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Medicine |
publisher.none.fl_str_mv |
Medicine |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRN instname:Universidade Federal do Rio Grande do Norte (UFRN) instacron:UFRN |
instname_str |
Universidade Federal do Rio Grande do Norte (UFRN) |
instacron_str |
UFRN |
institution |
UFRN |
reponame_str |
Repositório Institucional da UFRN |
collection |
Repositório Institucional da UFRN |
bitstream.url.fl_str_mv |
https://repositorio.ufrn.br/bitstream/123456789/55362/1/RituximabSystemicSclerosis_Piuvezam_2019.pdf https://repositorio.ufrn.br/bitstream/123456789/55362/2/license_rdf https://repositorio.ufrn.br/bitstream/123456789/55362/3/license.txt |
bitstream.checksum.fl_str_mv |
4d56cd6ea0810fb390744fb07b9d5bde 4d2950bda3d176f570a9f8b328dfbbef e9597aa2854d128fd968be5edc8a28d9 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN) |
repository.mail.fl_str_mv |
|
_version_ |
1797777040737304576 |